Deal Spotlight
August 14, 2026
Vivid Dx raises €13.2M Seed backed by Cedars-Sinai Intellectual Property Co, Jameel Investment Management Company, Oxford Sciences Enterprises
€13.2M
round size
seed
stage
The funding round closed on July 29, 2026, with participation from Cedars-Sinai Intellectual Property Co, Jameel Investment Management Company, and Oxford Sciences Enterprises. The company has no prior rounds and reported no total funds raised before this investment.
Vivid Dx develops a diagnostic platform for early cancer detection using liquid biopsy and circulating tumour DNA for non-invasive, accurate screening. The company is based in the United Kingdom and operates in Healthcare & Life Sciences.
Brouky tracks 269 deals in Healthcare & Life Sciences in the UK over the last 12 months with a median deal size of €11.2M.
Related insights
- Cross-Country AnalysisUS and Israeli startups show near-identical median times from Series B to C+ rounds
- Deal SpotlightAnya raises €9.2M Pre Series A with Angel Investors Bristol
- Deal SpotlightHalo Health raises €64.4M Series B1 with Ryan Smith
- Stage AnalysisUS Seed Round Counts Rebound in 2025 While Median Sizes Surge Over 2× Since 2023
Explore the full dataset
Brouky tracks 36,000+ investors and 100,000+ investments across 84,000+startups. Search by country, stage, and sector.